Clinical Research Studies Support Economic Growth and Development During A Pandemic, While Making a Global Difference
Springfield, Missouri; November 12, 2020 – QPS announced today that the Springfield campus is projecting to pay out more than $1 Million in stipends to area clinical research participants during the 4th Quarter of 2020. Of that $1 Million paid out in stipends, more than $840,000 is expected to be paid out in December 2020.
QPS Missouri is a Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. Study participants are paid a stipend for their participation and involvement in Clinical Research Studies. Those stipends from QPS benefit both the study participants and the economy, especially now, during the COVID-19 pandemic.
“Our participants are a key part of our success and have made a difference by giving their time to help advance drug research. “states Brendon Bourg, Vice President and General Manager QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community during a pandemic, is something we (QPS) are very proud and honored to be a part of.”
Located in Springfield, Missouri, QPS been conducting clinical trials for more than 26 years, with the help of more than 50,000 participants. The Springfield campus houses five independent clinics, a pharmacy with retention area, multiple labs and more than 240 beds. In addition, QPS Missouri is opening a 2,500 square foot, negative pressure room, later this fall.
QPS has always been on the front line of phase 1 research in all areas of new pharmaceuticals. Earlier this fall QPS announced that they were to begin conducting COVID-19 vaccine trials. As an industry leader in clinical and vaccine research, as well as experience in safely and efficiently conducting clinical research on vaccines, QPS is well prepared to handle the COVID-19 vaccine trials. Some of the other vaccine trials conducted at the Springfield campus include influenza, dengue fever, smallpox, yellow fever, West Nile virus, hepatitis B, and Japanese encephalitis. All of these trials have put Springfield on the map as a location that produces a global impact on the development of vaccines. With the help of their community participants, QPS Missouri is looking forward to joining the fight against COVID-19.
Since opening its doors in Springfield in 1994, QPS has conducted over 2,000 FDA-regulated studies and paid out more than $35 Million to local participants. To learn more information on clinical research studies at QPS, you can visit their website at 417studies.com or call the Springfield Campus at 417.831.2048.
ABOUT QPS – GLOBALLY
QPS is a global Clinical Research Organization supporting the discovery, preclinical and clinical development of new pharmaceutical products. Headquartered in Newark, Delaware, QPS has 11 worldwide clinical research and development sites which house a mix of clinical research and laboratory facilities. Our clinical research sites are in two states (Missouri and Florida) and four other countries (Netherlands, Taiwan, China and India).